AbbVie completes acquisition of Aliada Therapeutics to enhance neuroscience development
Acquiring Company
AbbVie Inc.
Acquired Company
Aliada Therapeutics
North ChicagoBostonManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaBiotechnologyDescription
AbbVie completed the acquisition of Aliada Therapeutics, a company focused on the development of therapeutic solutions for Alzheimer's disease. With this acquisition, AbbVie aims to advance potentially disease-modifying therapies such as ALIA-1758 for Alzheimer's disease and bolster their neuroscience discovery and development efforts by leveraging Aliada's novel CNS drug delivery platform.
Quick answer
AbbVie Inc. is acquiring Aliada Therapeutics, announced December 11, 2024. AbbVie Inc. is based in North Chicago, Illinois, United States.
- How much did AbbVie Inc. pay for Aliada Therapeutics?
- The deal value was not disclosed.
- What does AbbVie Inc. do?
- Venture capital subsidiary of Abbvie
- Where are AbbVie Inc. and Aliada Therapeutics based?
- AbbVie Inc. is based in North Chicago, Illinois, United States. Aliada Therapeutics is based in Boston, Massachusetts, United States.
- Who are the decision-makers at AbbVie Inc?
- Fundz holds 2 contacts at AbbVie Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie completes acquisition of Nimble Therapeutics to expand its immunology pipeline (January 23, 2025)
- Eton Pharmaceuticals completes acquisition of Galzin® (zinc acetate) from Teva Pharmaceuticals USA, Inc. to advance treatment for Wilson Disease (January 5, 2025)
- AbbVie announces acquisition of Aliada Therapeutics, focusing on Alzheimer's disease and neuroscience pipeline (October 28, 2024)
- Celltrion acquires iQone Healthcare Switzerland to strengthen European expansion (November 14, 2024)
- Exicure, Inc. completes acquisition of GPCR Therapeutics USA Inc. to enhance its pipeline for cell and gene therapies (January 22, 2025)
- Cycle Pharmaceuticals completes acquisition of Banner Life Sciences, LLC to expand MS product portfolio (January 13, 2025)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Aliada Therapeutics?
Aliada Therapeutics was acquired by AbbVie Inc., based in North Chicago. The deal was reported on December 11, 2024. Venture capital subsidiary of Abbvie AbbVie Inc. is publicly traded (ABBV) and operates in Manufacturing.
When did AbbVie Inc. acquire Aliada Therapeutics?
AbbVie Inc.'s acquisition of Aliada Therapeutics was reported on December 11, 2024. AbbVie completed the acquisition of Aliada Therapeutics, a company focused on the development of therapeutic solutions for Alzheimer's disease. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Aliada Therapeutics do?
Biologics are transforming the treatment of numerous diseases, but many CNS diseases remain largely out of reach due to the challenge of crossing the blood-brain barrier and navigating the brain’s unique immune environment. It is privately held, operating in Biotechnology, and is based in Boston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.